glp 1 agonist heart disease Cardiovascular and mortality outcomes with GLP-1 receptor agonists vs other glucose-lowering drugs in individuals with NAFLD and type 2 diabetes: a large population-based matched cohort study | Diabetologia Cardiovascular Effects of Glucagon-Like Peptide-1

The global market for GLP-1 weight-loss medications alone was valued at around $13.84 billion in 2024 and is expected to grow at a compound annual growth rate (CAGR) of 18.54%, reaching nearly $48.84 billion by 2030

Are GLP-1 Medications Worth the Cost

Not only did she manage to lose 20 percent of her weight, she recalls that her joints did not ache as much and her blood sugar returned to healthy levels

Activation of the GLP- 1 receptor also prevents beta cell apoptosis

Healthcare providers must focus on educating patients about GLP-1RA-related skin reactions and closely monitor them to achieve the best treatment results

There are several options in the market, but you need to identify your goal